Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ECG Exercise Stress Test in Coronary Artery Disease
Author(s): Gaetano Antonio Lanza Added: 7 months ago

Guidelines & Statements
Oxidative Stress Genes Predict Survival in STEMI
Author(s): Shuo-wen Sun , Xing-jie Wang , Ruo-chen Yan , et al Added: 9 months ago

MI/ACS

Prevention & Chronic Conditions
Echo-stress in Myocardial Bridge
Author(s): Priscilla Lamendola , Nello Cambise , Antonio Di Renzo , et al Added: 1 year ago

Prevention & Chronic Conditions
HFSA 25: The ATTRibute-CM Trial
Author(s): Ahmad Masri Added: 3 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more

Heart Failure
Author(s): Priscilla Lamendola , Nello Cambise , Antonio Di Renzo , et al Added: 1 year ago

Prevention & Chronic Conditions
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies
Author(s): Marianna Fontana Added: 2 years ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients. Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin… View more

Heart Failure
ESC 23: ATTRibute-CM Trial
Author(s): Julian Gillmore Added: 2 years ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935). ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were… View more

Heart Failure
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
Cardiomyopathies: Management of Cardiomyopathies with Dr Michelle Kittleson
Author(s): Michelle Kittleson Added: 6 months ago
Learn about the management of HFrEF and HFpEF from Dr Michelle Kittleson (Cedars-Sinai Heart Institute, Los Angeles, US).This two-part video lecture series, part of Women As One's CLIMB® 2025 Skills Training Program, provides a comprehensive overview of key treatments and therapy approaches to cardiomyopathies.In this lecture, Dr Kittleson provides an in-depth review of the management of HFrEF… View more

Heart Failure
Genetic Dilated Cardiomyopathy with Dr Nosheen Reza
Author(s): Nosheen Reza Added: 2 months ago
Explore the clinical approach to identifying and managing genetic dilated cardiomyopathy (DCM) with Dr Nosheen RezaThis presentation, part of the comprehensive Cardiomyopathies track, demonstrates how comprehensive family history assessment and systematic genetic evaluation can transform the diagnosis and management of patients presenting with dilated cardiomyopathy, revealing familial patterns… View more

CV Disease in Special Populations

Imaging & Diagnostics